Scilex Holding Operating Income Over Time
| SCLXW Stock | 0.15 0.01 4.69% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Scilex Holding Performance and Scilex Holding Correlation. What growth prospects exist in Biotechnology sector? Can Scilex capture new markets? Factors like these will boost the valuation of Scilex Holding. If investors know Scilex will grow in the future, the company's valuation will be higher. Valuation analysis balances hard financial data with qualitative growth assessments. While each Scilex Holding valuation metric matters, prioritizing which indicators carry greater predictive weight remains essential.
The market value of Scilex Holding is measured differently than its book value, which is the value of Scilex that is recorded on the company's balance sheet. Investors also form their own opinion of Scilex Holding's value that differs from its market value or its book value, called intrinsic value, which is Scilex Holding's true underlying value. Investment professionals apply varied valuation frameworks to compute inherent worth and acquire positions when market prices trade at discounts to calculated value. Because Scilex Holding's market value can be influenced by many factors that don't directly affect Scilex Holding's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Scilex Holding's value and its price as these two are different measures arrived at by different means. Investors typically determine if Scilex Holding is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. Meanwhile, Scilex Holding's quoted price indicates the marketplace figure where supply meets demand through bilateral consent.
Cross Equities Operating Income Analysis
Compare Scilex Holding and related stocks such as Creative Medical Tec, Aprea Therapeutics, and Adial Pharmaceuticals Operating Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CELZ | (1.4 K) | (19.8 K) | (20.1 K) | (20.1 K) | (19.4 K) | (20.8 K) | (766.1 K) | (1.2 M) | (1.1 M) | (1.1 M) | (1.1 M) | (3.1 M) | (10.2 M) | (5.6 M) | (5.7 M) | (5.2 M) | (4.9 M) |
| APRE | (3.2 M) | (21.3 K) | (21.3 K) | (246.5 K) | (15.9 M) | (15.9 M) | (15.9 M) | (15.9 M) | (16.5 M) | (29.5 M) | (52.8 M) | (37.4 M) | (113.4 M) | (15.5 M) | (14.3 M) | (12.9 M) | (13.5 M) |
| ADIL | (819.3 K) | (819.3 K) | (819.3 K) | (819.3 K) | (819.3 K) | (819.3 K) | (410.8 K) | (995.3 K) | (7 M) | (8.2 M) | (10.9 M) | (19.3 M) | (10.9 M) | (6.9 M) | (8.3 M) | (7.5 M) | (7.8 M) |
| KPRX | (5.9 M) | (5.9 M) | (5.9 M) | (3.1 M) | (2.5 M) | (6.7 M) | (13.3 M) | (14.6 M) | (10.8 M) | (7 M) | (6.9 M) | (14.2 M) | (12.3 M) | (12.6 M) | 4.5 M | 4.1 M | 4.3 M |
| CDIO | (609.2 K) | (609.2 K) | (609.2 K) | (609.2 K) | (609.2 K) | (609.2 K) | (609.2 K) | (609.2 K) | (609.2 K) | (609.2 K) | (609.2 K) | (620.4 K) | (4.5 M) | (7.2 M) | (8.4 M) | (7.5 M) | (7.2 M) |
| PHIO | (12.8 M) | (12.8 M) | (13 M) | (20.9 M) | (8.8 M) | (10.2 M) | (9 M) | (14.1 M) | (7.4 M) | (9 M) | (8.8 M) | (13.5 M) | (11.5 M) | (10.8 M) | (7.4 M) | (8.5 M) | (8.9 M) |
Scilex Holding and related stocks such as Creative Medical Tec, Aprea Therapeutics, and Adial Pharmaceuticals Operating Income description
Operating Income is the amount of profit realized from Scilex Holding operations after accounting for operating expenses such as cost of goods sold (COGS), wages and depreciation. Operating income takes the gross income and subtracts other operating expenses and then removes depreciation. Operating Income of Scilex Holding is typically a synonym for earnings before interest and taxes (EBIT) and is also commonly referred to as operating profit or recurring profit. Earnings before interest and taxes (EBIT), representing the amount of profit a company generates from its operations.My Equities
My Current Equities and Potential Positions
| Scilex Holding | SCLXW |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Business Address | 960 San Antonio |
| Exchange | NASDAQ Exchange |
null 0.1525
Additional Tools for Scilex Stock Analysis
When running Scilex Holding's price analysis, check to measure Scilex Holding's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Scilex Holding is operating at the current time. Most of Scilex Holding's value examination focuses on studying past and present price action to predict the probability of Scilex Holding's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Scilex Holding's price. Additionally, you may evaluate how the addition of Scilex Holding to your portfolios can decrease your overall portfolio volatility.